Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANLNASDAQ:CADLNASDAQ:GOSSNASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.86-6.8%$1.94$1.10▼$10.70$68.63M-0.9912,890 shs80,965 shsCADLCandel Therapeutics$5.57-4.8%$5.24$3.79▼$14.60$279.07M-0.921.45 million shs373,861 shsGOSSGossamer Bio$1.15+1.3%$1.01$0.50▼$1.55$260.26M1.821.54 million shs364,545 shsOCGNOcugen$0.86+2.6%$0.73$0.52▼$1.98$249.69M4.214.14 million shs1.40 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+9.42%+12.46%+0.81%-12.12%-75.96%CADLCandel Therapeutics-1.52%+7.93%+20.87%-34.86%-33.45%GOSSGossamer Bio-2.59%-2.59%+28.16%-8.13%+93.46%OCGNOcugen-5.57%-8.72%+14.60%+28.00%-48.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye1.5838 of 5 stars3.53.00.00.01.80.00.0CADLCandel Therapeutics1.9602 of 5 stars3.51.00.00.02.31.70.6GOSSGossamer Bio3.9605 of 5 stars3.52.00.04.73.21.70.0OCGNOcugen0.9116 of 5 stars3.50.00.00.01.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 3.00Buy$9.00383.87% UpsideCADLCandel Therapeutics 3.00Buy$21.00277.02% UpsideGOSSGossamer Bio 3.00Buy$7.75576.86% UpsideOCGNOcugen 3.00Buy$6.00600.93% UpsideCurrent Analyst Ratings BreakdownLatest ANL, GOSS, CADL, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/18/2025GOSSGossamer BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/14/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.003/6/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/6/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M13.73N/AN/AN/A∞CADLCandel Therapeutics$120K2,325.61N/AN/A$0.44 per share12.66GOSSGossamer Bio$124.59M2.09N/AN/A$0.28 per share4.09OCGNOcugen$4.52M55.28N/AN/A$0.16 per share5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$104.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)CADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)GOSSGossamer Bio-$179.82M-$0.23N/AN/AN/AN/A-127.28%-22.12%8/11/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%8/14/2025 (Estimated)Latest ANL, GOSS, CADL, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 million3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/A3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A1.85N/ACADLCandel TherapeuticsN/A1.181.18GOSSGossamer Bio3.646.746.74OCGNOcugen0.042.582.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%CADLCandel Therapeutics13.93%GOSSGossamer Bio81.23%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ACADLCandel Therapeutics16.60%GOSSGossamer Bio6.70%OCGNOcugen4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableGOSSGossamer Bio180227.30 million215.27 millionOptionableOCGNOcugen80292.03 million278.82 millionOptionableANL, GOSS, CADL, and OCGN HeadlinesRecent News About These CompaniesOcugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathiesMay 27 at 6:31 PM | ophthalmologytimes.comOcugen wins FDA rare pediatric disease status for genetic eye disorder treatmentMay 27 at 6:31 PM | msn.comOcugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated RetinopathiesMay 27 at 7:19 AM | quiverquant.comOcugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt DiseaseMay 27 at 7:02 AM | globenewswire.comNoble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)May 16, 2025 | marketbeat.comThe Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 14, 2025 | nasdaq.comOcugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC WainwrightMay 14, 2025 | marketbeat.comOcugen's (OCGN) "Buy" Rating Reiterated at Chardan CapitalMay 14, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPSMay 13, 2025 | marketbeat.comOcugen Reports Progress in Q1 2025 with Advancements in Gene TherapyMay 13, 2025 | msn.com1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 13, 2025 | benzinga.comOcugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOcugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns BullishMay 9, 2025 | msn.comOcugen, Inc. (OCGN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comOcugen Provides Business Update with First Quarter 2025 Financial ResultsMay 9, 2025 | globenewswire.comA Look at Ocugen's Upcoming Earnings ReportMay 9, 2025 | benzinga.comOcugen (OCGN) Projected to Post Earnings on FridayMay 6, 2025 | marketbeat.comOcugen to Host Q1 2025 Earnings Call and Business Update on May 9May 5, 2025 | msn.comOCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and MoreMay 2, 2025 | nasdaq.comOcugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comOcugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology ConferencesMay 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi Orders3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest LoserBy Leo Miller | May 13, 2025View 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest LoserANL, GOSS, CADL, and OCGN Company DescriptionsAdlai Nortye NASDAQ:ANL$1.86 -0.14 (-6.77%) As of 12:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Candel Therapeutics NASDAQ:CADL$5.57 -0.28 (-4.79%) As of 12:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Gossamer Bio NASDAQ:GOSS$1.14 +0.02 (+1.33%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Ocugen NASDAQ:OCGN$0.86 +0.02 (+2.61%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
